Roche’s quantitative COVID-19 antibody test; Janssen buys a gene therapy asset; Zimmer Acquires A&E Medical; Glaucoma research study: Merck chooses TriNKET cancer immunotherapy program; Ovid fails Angelman phase 3 study
Delveinsight
DECEMBER 3, 2020
Roche has got an authorization from the FDA for a more accurate COVID-19 blood test capable of measuring the levels of specific antibodies, which target the cell-unlocking spike protein of coronavirus. An overactivity of complement damages cells in the macula in geographic atrophy. Merck chooses TriNKET cancer immunotherapy program.
52 
Let's personalize your content